In August, the retail sales of national passenger car market of China charted 1.952 million units, marking a YoY rise of 3% and an MoM hike of 7%, the China Passenger Car Association (CPCA)'s preliminary statistics showed. The total retail sales so far this year have grossed 14.698 million units, a YoY increase of 9%.

In August, the wholesale volume of the national passenger car manufacturers was 2.409 million units, a YoY upswing 12% and an MoM elevation of 8%. The cumulative wholesale volume so far this year has reached 17.934 million units, a YoY gain of 12%.

In the new energy vehicle (NEV) market, the retail sales of the national passenger NEV market in August were 1.079 million units, a YoY growth of 5% and an MoM rise of 9%. The national NEV market retail penetration rate was 55.3%. The cumulative retail sales so far this year were 7.535 million units, up 25% YoY.
~



AASTOCKS Financial News
Website: www.aastocks.com

香港2025年9月3日 /美通社/ -- 隨着中國移動集團正式成為「第十五屆全國運動會（十五運會）及全國第十二屆殘疾人運動會暨第九屆特殊奧林匹克運動會（殘特奧會）」的官方合作夥伴，中國移動香港（CMHK）作為全資附屬公司，將透過先進多元的網絡部署，全力支持香港地區賽事，並提供全面貼心的服務與支援，滿足全運會期間港人北上及內地旅客南下的通訊需求，確保國家盛事順利舉行。

極速連繫 盡享全運
今屆賽事將於 11 月盛大舉行，並首度由廣東、香港及澳門三地聯合主辦，標誌着全國體壇的重要里程碑。其中，香港將承辦 8 個運動項目，包括在巴黎奧運表現出色的劍擊賽事，體現香港作為國際體育舞台的重要角色。相關比賽將於多個具代表性的地點舉行，如啟德體育園、香港體育館、維多利亞公園及粉嶺高爾夫球場等，屆時將吸引大批市民及旅客現場欣賞賽事。

全運網絡 無縫接軌
CMHK結合中國移動龐大資源優勢，充分發揮 5G 網絡領先地位，憑藉擁有香港最多頻譜資源的本地流動網絡營運商之一¹，為市民及賽事觀眾帶來極致流暢的網絡體驗。為應對賽事期間龐大的通訊需求，CMHK 將特別在比賽場館及周邊地區提前部署應急通訊車，採用衛星、微波、光纖等多種先進傳輸技術，提供涵蓋 700MHz 至 4.9GHz 的全頻段大容量網絡服務，猶如一個流動基站，保障場館內外通訊無阻。在去年的國慶 75 周年煙花匯演中，CMHK 應急通訊車成功於現場維持高達 30Mbps 上載及 380Mbps 下載速度，並有效將現場一帶的網絡容量提升達 2.4 倍，充分展現其在大型活動中保障通訊的強大實力，進一步突顯 CMHK 卓越網絡及服務的領先地位。

CMHK 亦於全運會期間引入先進的 5G 智能無線調度系統，能夠根據用戶分佈與網絡負荷情況，實時動態調整資源，讓每一位用戶在不同場景下都能享受優質的上網體驗。此外，CMHK 的 Privilege Club 鑽石咭會員更可享用「網絡頭等艙²」服務，獲得網絡最優先接入權，即使身處人流密集的場館或場地，仍能享受更快、更穩定的高速上網體驗。

服務保障 加強防詐
除了網絡優化，CMHK 亦透過人力與技術結合，提供全天候的專線服務及智慧自助查詢，並以全方位智能即時監察，快速處理賽事期間客戶遇到的各類通訊問題；CMHK 同時加強防詐騙工作，將配合香港政府的相關行動或視乎最新詐騙手法，在全運會期間展開針對性的防詐騙宣傳，提醒客戶提防不法分子利用賽事相關活動進行詐騙，從而保障客戶財產安全。

無縫漫遊 Link盡著數
全運會期間，不少市民會遊走粵、港、澳欣賞現場精彩賽事。CMHK「5G一咭三地服務計劃」貼心為市民提供更便利的跨境通訊體驗，客戶只需一個月費，即可於中國內地、香港及澳門三地共享數據，無需換卡即可暢享無縫漫遊，並可隨心使用Facebook、Instagram、WhatsApp和YouTube等港人常用應用程式，隨時隨地與親友保持聯繫，分享比賽點滴。此外，用戶更可透過 「Link著數會員（灣區版）³」，進一步享受深圳、珠海等大灣區城市的多元消費優惠，涵蓋購物、餐飲、娛樂、汽車服務等範疇，合作商場包括皇庭廣場、領展中心城、深業上城等多個人氣地點。只需於 MyLink App 選購商場通用電子消費券「移動優享券」，即可直接在合作商戶的實體店使用，輕鬆方便。除了大灣區生活，「Link著數會員（灣區版）」亦涵蓋多個香港本地權益，圍繞本地大型超市、熱門咖啡店鋪等，為用戶的日常生活增添更多額外折扣。

為與香港市民一同迎接這場國家級體壇盛事，CMHK 秉承「以客為先」的承諾，精益求精，努力成為客戶通訊的堅實後盾；更將陸續推出多項與全運會相關的優惠和驚喜活動，務求與市民共享喜悅。市民只需關注 CMHK 官方網站及社交平台，便可率先掌握最新活動詳情，精彩內容敬請期待。

關於中國移動香港有限公司
中國移動香港有限公司（簡稱「中國移動香港」）隸屬中國移動有限公司（簡稱「中國移動」），《財富》雜誌「全球500強」企業，香港聯交所股份代號：941；於1997年1月正式提供服務，成為全港首個PCS流動網絡商。

作為全球最多客戶流動網絡品牌*，公司透過5G SA/NSA、4G LTE等技術為客戶提供創新及多元化的通訊服務，包括話音、數據、IDD及國際漫遊等，並一直致力發展5G與人工智慧、物聯網、雲端計算、大數據等新技術結合，幫助各行各業實現5G的應用，推動大灣區智慧城市群建設與發展。

Li Yunfei, General Manager of Brand and PR at BYD COMPANY (01211.HK)(002594.SZ), stated that the company has set an overseas sales target of 800,000 vehicles for the entire year, and based on current market performance, it should be no problem to achieve this goal this year.

He also mentioned that Chinese auto brands are hailing the best globalization window, and more Chinese brands will enter the global top ten in the future, describing it as an inevitable result of the transformation and upgrading of China's manufacturing industry.

BYD will in the future continue to adhere to the development philosophy of "technology as king, innovation as the foundation", deepening globalization and localization strategies, he added. Global car companies like Volkswagen, Tesla (TSLA.US), and Toyota are already globalized, and the globalization of Chinese auto brands, including BYD, is just beginning.

He believed that more Chinese brands will enter the global top ten in the future, which is an inevitable trend and the mission of this generation of automotive professionals.
~



AASTOCKS Financial News
Website: www.aastocks.com

Investors eyed on the surge in U.S. bond yields, prompting U.S. stocks to plunge on Tuesday after reopening from a long holiday, although they recovered some losses before the close. The DJIA slid nearly 600 points or 1.3% during the session, busting below 45,000, and ultimately closed down 249 points or 0.6% at 45,295. The S&P 500 dipped 44 points or 0.7% to 6,415. The Nasdaq sank 175 points or 0.8% to 21,279.

Nvidia (NVDA.US) fell off 4% at one point, but later posted a denial of chip woe rumors, stating that it has sufficient H100 and H200 chips to fulfill every order without delivery delays, narrowing its loss to 2% by the close. Some investors took profits, with techs being the main focus of selling. Amazon (AMZN.US) and Apple (AAPL.US) both sagged over 1%. Tesla (TSLA.US) began delivery of its first batch of Model YL in China, with August sales of China-made vehicles rebounding 22% MoM, yet the stock still lost 1.4%.

NIO (NIO.US) delivered a record 31,305 vehicles in August, but its adjusted earnings and revenue for the last quarter were disappointing, causing the stock to initially fall before stabilizing and swelling over 3%.
~



AASTOCKS Financial News
Website: www.aastocks.com

Nvidia (NVDA.US) refuted media reports claiming that it was unable to fulfill new orders for its H100 and H200 GPU chips on Tuesday.

Nvidia posted on social platform X that it has sufficient H100 and H200 to meet every order without delay. The production of H20 chips does not affect the supply of H100, H200 and Blackwell chips. The Company emphasized that the sales of H20 do not impact its ability to supply other Nvidia products.

Recently, news media reported a market shortage of older Nvidia chips, including H100 and H200, as China's AI industry turned to older Nvidia GPUs following the ban on using Nvidia H20 chip.
~

AASTOCKS Financial News
Website: www.aastocks.com

NVIDIA (NVDA.US) once slumped 4% to US$167 on Tuesday, marking its fourth consecutive day of decline. The breach of this level suggested a weakening of short-term momentum, which may pressure the stock's outlook, analysts said.

Recently, the market has been affected by geopolitical concerns and high valuation worries, leading to a general slide in tech stocks.

NVIDIA has eroded more than 7% over four days, with its market cap evaporating by over US$340 billion. However, the company remains the world's largest by market cap at approximately US$4.1 trillion, far surpassing Microsoft's US$3.7 trillion.
~



AASTOCKS Financial News
Website: www.aastocks.com

The wholesale sales of passenger new energy vehicles (NEVs) numbered 1.3 million units in China in August, notching a 24% YoY elevation and a 10% MoM increment, as the China Passenger Car Association (CPCA) released preliminary monthly data estimating.

It was expected that cumulative wholesale sales for 8M25 reached 8.93 million units, representing a 34% YoY growth.
~



AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, Sept. 2, 2025 /PRNewswire/ -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study evaluating ivonescimab, in combination with standard therapy, against durvalumab (PD-L1) combination therapy, for the first-line treatment of advanced biliary tract cancer (BTC) (AK112-309/HARMONi-GI1). This Phase III trial is being conducted in China.

Ivonescimab has previously shown significant positive results in the randomized, double-blind, controlled Phase III study (HARMONi-2), where it was compared head-to-head with pembrolizumab. These results led to its approval as a first-line treatment for PD-L1-positive non-small cell lung cancer (NSCLC), marking its second approved indication. In addition, the Phase III trial of ivonescimab in combination with chemotherapy compared to tislelizumab combined with chemotherapy as a first-line treatment for squamous NSCLC, also delivered significant positive outcomes. These results highlight ivonescimab's strong clinical breakthroughs. Whether compared to PD-1 monotherapy, PD-1 plus chemotherapy (current standard therapies for various cancers), or VEGF-related treatments, ivonescimab has consistently demonstrated its ability to drive clinical innovation.

Ivonescimab continues to validate its clinically meaningful profile and potential with a strategically expanded development program targeting key immuno-oncology settings:

Phase III trials for Lung cancer (8 registrational/Phase III trials, 4 already met primary endpoints):

• First-line NSCLC, squamous and non-squamous (versus pembrolizumab + chemotherapy; global trial)
• First-line squamous NSCLC (versus tislelizumab + chemotherapy)
• NSCLC after progression on EGFR-TKI therapy (HARMONi-A and HARMONi studies)
• First-line PD-L1-positive NSCLC (versus pembrolizumab monotherapy)
• First-line PD-L1-high expressing NSCLC (versus pembrolizumab)
• IO-resistant NSCLC
• Consolidation therapy for limited-stage small cell lung cancer (LS-SCLC) without progression after concurrent chemoradiotherapy (cCRT)

Phase III trials for core immuno-oncology indications (first-line therapy ):

• First-line biliary tract cancer (versus durvalumab + chemotherapy)
• First-line PD-L1-positive head and neck squamous cell carcinoma (HNSCC) in combination with ligufalimab (anti-CD47) versus pembrolizumab

Phase III trials for cold tumors and more:

• First-line triple-negative breast cancer (TNBC)
• First-line MSS/pMMR colorectal cancer (representing about 95% of CRC cases)
• First-line pancreatic cancer
• Additional global Phase III trials are in advanced stages of planning

An extensive clinical foundation includes over 20 Phase II studies across more than 10 additional tumor types, generating compelling efficacy and safety data that enable rapid transition to further registrational studies worldwide.

Ivonescimab uniquely targets both PD-1 and VEGF, producing a synergistic anti-tumor effect. This dual mechanism not only combines the benefits of PD-1 and VEGF inhibition but also overcomes the efficacy and safety limitations of each target alone, resulting in pronounced clinical benefits. These advantages have been confirmed across multiple Phase III trials and real-world use, rapidly establishing ivonescimab as a next-generation leader in immunotherapy and anti-angiogenic therapy.

For context, pembrolizumab (anti-PD-1) is approved for over 40 oncology indications, and bevacizumab (anti-VEGF) for more than 10. Akeso is implementing a dual-path strategy to maximize the value of ivonescimab worldwide: accelerating domestic commercialization and label expansion in China, while simultaneously advancing global development in partnership with Summit Therapeutics.

Forward-Looking Statement of Akeso, Inc.
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

香港2025年9月2日 /美通社/ -- 在中國持續推進綠色低碳發展的背景下，光大環境（00257.HK）作為環保行業的領軍企業，2025年圍繞完善科研管理架構、聚焦重點研發方向及深化成果轉化應用等目標，在科技創新領域取得紮實進展。

管理架構完善驅動科研體系升級

2025年，光大環境依托科技委員會，系統性構建起覆蓋課題管理、成果轉化、考核激勵的全流程科研製度框架。通過修訂完善《科技經費管理辦法》等核心製度，顯著提升了科研管理的規範性與效率，為持續創新奠定堅實基礎。

「3+1」重點研發方向成果顯現

集團系統梳理在研課題，結合業務需求，著重跟進「3+1」重點課題研發及成果應用轉化。其中飛灰資源化利用技術實現工藝突破，助力集團推進相關項目落地；垃圾製碳技術研究有序推進；生物質糖化等高值化利用研究取得進展，助力業務板塊打造示範項目；微型爐排爐技術探索穩步開展。

在成果轉化方面，中國首個垃圾發電項目厭氧氨氧化系統在浙江寧海垃圾發電項目調試成功，200噸/日小型爐成套設備在河北廣宗垃圾發電項目進入安裝調試階段。同時，自動燃燒控製(ACC)、半幹法煙氣自動控製(AFC)、高分子非催化還原(PNCR)、地磅自動化改造系統、脫硫脫硝一體化等技術轉化持續推進。

其中，厭氧膜生物反應器(MBR)處理滲濾液技術經鑒定達到國際領先水平，為下一步加大成果轉化力度奠定良好基礎。小型爐設備經鑒定整體達到國際先進水平，其核心的「多源固廢協同焚燒技術」達到國際領先水平。

數字化平臺建設持續推進

2025年上半年，光大環境管理數智化建設成效顯著。業財一體化等數字化平臺建設工作持續深化。裝備雲服智能平臺正式上線，該平臺聚焦環保設備全生命周期數字化服務，涵蓋備件商城、智能詢報價、智能維保服務等模塊，截至2025年6月30日，平臺註冊用戶約600家。

知識產權與權威認可再獲豐收

2025年上半年，光大環境新增授權知識產權共計91項，其中發明專利35項、實用型專利50項、軟件著作專利6項，同時期發表重要論文2篇。截至2025年6月30日，集團累計持有授權知識產權超過2,200項，其中發明專利317項、實用型專利1,530項、軟件著作專利338項、外觀專利55項；重要論文發表累計達到104篇。

集團創新成果獲得多項權威認可：

• 水冷爐排成套裝備和電池回收資源化利用成套設備，成功入選工業和信息化部「首臺（套）重大技術裝備保險補償項目」。
• 自主研發的水冷流道溫度計流量監測系統及方法和流道參數測試系統專利項目，榮獲國家知識產權局頒發的「中國專利優秀獎」。
• 環保能源板塊與華中科技大學聯合申報的「生活垃圾收運處理及資源化全過程減汙降碳關鍵技術與應用」，獲中國環境科學學會「科技進步一等獎」。
• 與浙江大學共同研發推廣的「多源城市有機垃圾高效能源化及協同消納關鍵技術」，榮膺中國產學研促進會「2024年中國產學研合作促進會科技創新獎創新成果二等獎」。
• 自主研發的飛灰低溫熱解水洗技術通過生態環境部南京環境科學研究所組織的專家評審，獲得權威認可，被認為工藝技術可行，具有行業推廣意義。

集團依托環境研究院這一科技研發創新的引擎，專註以科技賦能各業務板塊發展，在「3+1」重點方向攻關與成果轉化方面持續發揮核心平臺作用，以創新驅動實現高質量發展提供強勁動力。

展望未來，光大環境將持續扮演綠色科技創新的引領者角色，以前沿技術突破、高效成果轉化與堅實的知識產權布局，深耕環保產業價值鏈核心環節，不斷鞏固技術護城河，驅動業務模式升級與運營效能躍升，為中國乃至全球的綠色低碳轉型貢獻更具價值的「光大創新方案」。

NVIDIA (NVDA.US) CEO Jensen Huang will attend The APEC Economic Leaders' Meeting in Gyeongju, South Korea, in October. South Korea's Chosun Ilbo reported.

The South Korean government has been in contact with NVIDIA through multiple channels to ensure Huang's attendance, which has recently been confirmed, the report quoted senior officials from South Korea's ruling party as saying.

The summit will include a conference on driving economic development through artificial intelligence, where Huang is expected to play a leading role.

The report also mentioned that South Korea is inviting OpenAI CEO Sam Altman, Google CEO Sundar Pichai, and Apple CEO Tim Cook to attend.
~



AASTOCKS Financial News
Website: www.aastocks.com